Dr. Michael Kelly

Dr. Michael Kelly

Assistant Professor, Pharmacy Practice
School of Pharmacy
Expertise: Dyslipidemia; Diabetes; Hypertension; Chronic Disease Management; Ambulatory Blood Pressure Monitoring;
Office Location: Rinker Health Science Campus 297D
Grand Valley State University, Bachelor of Science
Virginia Commonwealth University, Doctor of Pharmacy


Dr. Kelly earned a Bachelor of Science degree in Biochemistry/Biotechnology from Grand Valley State University, followed by a Doctor of Pharmacy degree from Virginia Commonwealth University in Richmond, VA.  Dr. Kelly’s residency training included a PGY1 ambulatory care residency at VCU, followed by a PGY2 ambulatory care/family medicine residency at the University of Colorado Anschutz Medical Campus.  As a resident, Dr. Kelly managed multiple chronic disease states under pharmacist-physician collaborative protocols in a diverse patient population, including uninsured and undocumented patients.  His residency training also had a large focus on teaching, where he served as a clinical instructor and received a teaching certificate.

Research interests:

Dr. Kelly’s research interests include the use of ambulatory blood pressure monitors to treat hypertension, chronic disease management in underserved populations, cardio-metabolic disease states, and teaching with the use of technology.

Recent Creative, Scholarly Work and Publications

Kelly MS, Saseen JJ, Marrs JC. Assessment of achieved systolic blood pressure in newly treated hypertensive patients aged 60-79 years before and after Eighth Joint National Committee recommendations. Ther Adv Cardiovasc Dis. 2017 Feb;11(2):63-71. doi: 10.1177/1753944716684463.
Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate A, Dixon DL. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017 May 18;6(5).
Kelly MS, Beavers C, Bucheit JD, Sisson EM, Dixon DL. Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg/dL). J Clin Lipidol. 2017 Jun 6. pii: S1933-2874(17)30340-9. doi: 10.1016/j.jacl.2017.05.014. [Epub ahead of print]